Topoisomerase II Inhibitors
"Topoisomerase II Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
| Descriptor ID |
D059005
|
| MeSH Number(s) |
D27.505.519.389.892.750 D27.505.954.248.794.750
|
| Concept/Terms |
Topoisomerase II Inhibitors- Topoisomerase II Inhibitors
- Inhibitors, Topoisomerase II
- DNA Type 2 Topoisomerase Inhibitors
- Topoisomerase 2 Inhibitors
- Inhibitors, Topoisomerase 2
- DNA Topoisomerase II Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase II Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase II Inhibitors".
This graph shows the total number of publications written about "Topoisomerase II Inhibitors" by people in this website by year, and whether "Topoisomerase II Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase II Inhibitors" by people in Profiles.
-
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012 Jun; 97(6):919-25.
-
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol. 2008 Jun; 31(3):219-25.
-
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80.
-
Assessing sensitivity to antibacterial topoisomerase II inhibitors. Curr Protoc Pharmacol. 2007 Dec; Chapter 3:Unit3.13.
-
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther. 2007 May; 6(5):1501-8.
-
Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)]. Arch Biochem Biophys. 2002 May 01; 401(1):53-62.
-
Temporospatial sequence of cellular events associated with etoposide-induced neuronal cell death: role of antiapoptotic protein Bcl-X(L). J Neurosci Res. 2001 Dec 15; 66(6):1074-82.
-
Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium. J Biosci. 2001 Jun; 26(2):271-6.
-
Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene. Arch Biochem Biophys. 2000 Apr 01; 376(1):229-35.
-
Heterogeneous apoptotic responses of prostate cancer cell lines identify an association between sensitivity to staurosporine-induced apoptosis, expression of Bcl-2 family members, and caspase activation. Prostate. 2000 Mar 01; 42(4):260-73.